Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207828 | 0.85 | TAAR1 (0.66) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL8747066 | 0.85 | TAAR1 (0.66) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL2430164 | 0.84 | HTR2B (0.49) | ADRA1ATAAR1HTR2BHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL27696218 | 0.82 | HTR2B (0.47) | ADRA1ATAAR1HTR2BHTR2ASLC6A4 | |
| SCHEMBL12523559 | 0.82 | TAAR1 (0.53) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL3761927 | 0.82 | L3MBTL1 (0.54) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL9144848 | 0.82 | ALDH1A1 (0.53) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL24252449 | 0.80 | SLC6A4 (0.46) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL772818 | 0.80 | SLC6A4 (0.46) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 | |
| SCHEMBL474102 | 0.80 | HTR2A (0.46) | ADRA1ATAAR1HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430036-B1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2014-03-06 | — | — | US | disclosed |
| CN-102822165-A | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORP | 2012-12-12 | — | — | CN | disclosed |
| WO-2012123467-A1 | PYRIMIDINE AMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1305454-A | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | PNP, NUDT1, TYMP | ADRA1A 3163/4885TAAR1 4462/4885HTR2B 2547/4885 |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | ADRA1A 183/4885TAAR1 1101/4885HTR2B 1337/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | ADRA1A 3423/4885TAAR1 4434/4885HTR2B 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.